Ertugliflozin for Functional Mitral Regurgitation (EFFORT)
Mitral Valve Insufficiency, Left Ventricular Systolic Dysfunction
About this trial
This is an interventional treatment trial for Mitral Valve Insufficiency
Eligibility Criteria
Inclusion Criteria:
- Patients must agree to the study protocol and provide written informed consent
- Outpatients ≥ 20 years of age, male or female
- Non-diabetic or type2 DM patients with HbA1c 7.0-10.5%
Patients with secondary functional MR (stage B and C) and LV dysfunction
- Symptoms due to coronary ischemia or heart failure may be present but symptoms due to MR should be absent
- Normal mitral valve leaflets and chords
- Regional or global wall motion abnormalities with mild or severe tethering of leaflet
- MR whose ERO > 0.10 cm2 and which lasted > 6 months under medical treatment with a β-blocker and an ACE inhibitor (or ARB)
- 35% < LV ejection fraction < 50%
- Dyspnea of NYHA functional class II or III
- Titration of HF medications should be completed and patients must take a stable, optimized dose of a β-blocker and an ACE inhibitor (or ARB) for at least 4 weeks prior to study entry
Exclusion Criteria:
- History of hypersensitivity or allergy to the study drug, drugs of similar chemical classes, or SGLT-2 as well as known or suspected contraindications to the study drug
- Current use or prior use of a SGLT-2 inhibitor or combined SGLT-1 and 2 inhibitor
- Known history of angioedema
- Any evidence of structural mitral valve disease, including prolapse of mitral leaflets and rupture of chords or papillary muscles
- Current acute decompensated heart failure or dyspnea of NYHA functional class IV
- Medical history of hospitalization within 6 weeks
- Symptomatic hypotension and/or a SBP < 100 mmHg at screening
- Estimated GFR < 45 mL/min/1.73m2
- History of ketoacidosis
- Evidence of hepatic disease as determined by any one of the following: AST or ALT values exceeding 2 x upper limit of normal (ULN) at screening visit (Visit 0), history of hepatic encephalopathy, history of esophageal varices, or history of portacaval shunt.
- Acute coronary syndrome, stroke, major CV surgery, PCI within 3 months
- Substantial myocardial ischemia requiring coronary revascularization, a plan of coronary revascularization or mitral valve intervention within 1 year
- Indication of cardiac resynchronization therapy, a plan of heart transplantation or implantation of cardiac resynchronization therapy
- History of severe pulmonary disease
- Significant aortic valve disease
- Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using a barrier method plus a hormonal method
- Pregnant or nursing (lactating) women
- Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the investigator, would preclude safe completion of the study
Sites / Locations
- Asan Medical Center
- Samsung Medical Center
- Seoul National University Hospital
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Active Comparator
Placebo
Ertugliflozin
All patients will receive placebo in addition to their usual medications. Titration of HF medications should be completed and patients must take a stable, optimized dose of a β-blocker and an ACE inhibitor (or ARB) for at least 4 weeks prior to study entry.
All patients will receive ertugliflozin 5 mg qd in addition to their usual medications. Titration of HF medications should be completed and patients must take a stable, optimized dose of a β-blocker and an ACE inhibitor (or ARB) for at least 4 weeks prior to study entry.